These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 26819748)
1. Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry. Mease PJ; Collier DH; Saunders KC; Li G; Kremer JM; Greenberg JD RMD Open; 2015; 1(1):e000181. PubMed ID: 26819748 [TBL] [Abstract][Full Text] [Related]
2. Persistence of tumor necrosis factor inhibitor or conventional synthetic disease-modifying antirheumatic drug monotherapy or combination therapy in psoriatic arthritis in a real-world setting. Mease PJ; Accortt NA; Rebello S; Etzel CJ; Harrison RW; Aras GA; Gharaibeh MMF; Greenberg JD; Collier DH Rheumatol Int; 2019 Sep; 39(9):1547-1558. PubMed ID: 31321485 [TBL] [Abstract][Full Text] [Related]
3. Persistence on biologic DMARD monotherapy after achieving rheumatoid arthritis disease control on combination therapy: retrospective analysis of corrona registry data. Pappas DA; Litman HJ; Lesperance T; Kricorian G; Karis E; Rebello S; Hua W; Accortt NA; Stryker S Rheumatol Int; 2021 Feb; 41(2):381-390. PubMed ID: 32876744 [TBL] [Abstract][Full Text] [Related]
4. Treatment patterns in rheumatoid arthritis patients newly initiated on biologic and conventional synthetic disease-modifying antirheumatic drug therapy and enrolled in a North American clinical registry. Mease PJ; Stryker S; Liu M; Salim B; Rebello S; Gharaibeh M; Collier DH Arthritis Res Ther; 2021 Sep; 23(1):236. PubMed ID: 34496952 [TBL] [Abstract][Full Text] [Related]
5. Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry. Harrold LR; Stolshek BS; Rebello S; Collier DH; Mutebi A; Wade SW; Malley W; Greenberg JD; Etzel CJ Clin Rheumatol; 2017 Apr; 36(4):895-901. PubMed ID: 28271234 [TBL] [Abstract][Full Text] [Related]
6. Changes in Treatment Patterns in Patients with Psoriatic Arthritis Initiating Biologic and Nonbiologic Therapy in a Clinical Registry. Mease PJ; Lesperance T; Liu M; Collier DH; Mason M; Deveikis S; Accortt NA J Rheumatol; 2017 Feb; 44(2):184-192. PubMed ID: 28089969 [TBL] [Abstract][Full Text] [Related]
7. Tumor Necrosis Factor Inhibitor Monotherapy Versus Combination Therapy for the Treatment of Psoriatic Arthritis: Combined Analysis of European Biologics Databases. Thomas ML; Shaddick G; Charlton R; Cavill C; Holland R; Iannone F; Lapadula G; Lopriore S; Závada J; Uher M; Pavelka K; Szczuková L; Sidiropoulos P; Flouri I; Drosos A; Möller B; Nissen MJ; Müller RB; Scherer A; McHugh N; Nightingale A J Rheumatol; 2021 Jan; 48(1):48-57. PubMed ID: 32238520 [TBL] [Abstract][Full Text] [Related]
8. Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry. Mease PJ; Karki C; Liu M; Li Y; Gershenson B; Feng H; Hur P; Greenberg JD RMD Open; 2019; 5(1):e000880. PubMed ID: 31168408 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Tumor Necrosis Factor Inhibitors in Combination with Various csDMARD in the Treatment of Rheumatoid Arthritis: Data from the DREAM Registry. Manders SH; Kievit W; Jansen TL; Stolk JN; Visser H; Schilder AM; Vonkeman HE; Adang E; van de Laar MA; van Riel PL J Rheumatol; 2016 Oct; 43(10):1787-1794. PubMed ID: 27481900 [TBL] [Abstract][Full Text] [Related]
10. Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims Database. Mease PJ; Young P; Gruben D; Fallon L; Germino R; Kavanaugh A Adv Ther; 2022 Jun; 39(6):2932-2945. PubMed ID: 35482248 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration. Lindström U; Di Giuseppe D; Delcoigne B; Glintborg B; Möller B; Ciurea A; Pombo-Suarez M; Sanchez-Piedra C; Eklund K; Relas H; Gudbjornsson B; Love TJ; Jones GT; Codreanu C; Ionescu R; Nekvindova L; Závada J; Atas N; Yolbas S; Fagerli KM; Michelsen B; Rotar Ž; Tomšič M; Iannone F; Santos MJ; Avila-Ribeiro P; Ørnbjerg LM; Østergaard M; Jacobsson LT; Askling J; Nissen MJ Ann Rheum Dis; 2021 Nov; 80(11):1410-1418. PubMed ID: 34083206 [TBL] [Abstract][Full Text] [Related]
12. Persistence of low disease activity after tumour necrosis factor inhibitor (TNFi) discontinuation in patients with psoriatic arthritis. Huynh DH; Boyd TA; Etzel CJ; Cox V; Kremer J; Mease P; Kavanaugh A RMD Open; 2017; 3(1):e000395. PubMed ID: 28123783 [TBL] [Abstract][Full Text] [Related]
13. Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry. Harrold LR; Litman HJ; Connolly SE; Alemao E; Kelly S; Rebello S; Hua W; Kremer JM Rheumatol Ther; 2019 Jun; 6(2):217-230. PubMed ID: 30868550 [TBL] [Abstract][Full Text] [Related]
15. Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis. Stober C; Ye W; Guruparan T; Htut E; Clunie G; Jadon D Rheumatology (Oxford); 2018 Jan; 57(1):158-163. PubMed ID: 29077973 [TBL] [Abstract][Full Text] [Related]
16. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Fagerli KM; Lie E; van der Heijde D; Heiberg MS; Lexberg AS; Rødevand E; Kalstad S; Mikkelsen K; Kvien TK Ann Rheum Dis; 2014 Jan; 73(1):132-7. PubMed ID: 23291385 [TBL] [Abstract][Full Text] [Related]
17. Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials. Emamikia S; Arkema EV; Györi N; Detert J; Chatzidionysiou K; Dougados M; Burmester GR; van Vollenhoven R RMD Open; 2016; 2(2):e000323. PubMed ID: 27651929 [TBL] [Abstract][Full Text] [Related]
18. Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis. Harrold LR; Reed GW; Best J; Zlotnick S; Kremer JM Rheumatol Ther; 2018 Dec; 5(2):507-523. PubMed ID: 30293218 [TBL] [Abstract][Full Text] [Related]
19. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry. Glintborg B; Ostergaard M; Krogh NS; Andersen MD; Tarp U; Loft AG; Lindegaard HM; Holland-Fischer M; Nordin H; Jensen DV; Olsen CH; Hetland ML Arthritis Rheum; 2013 May; 65(5):1213-23. PubMed ID: 23460467 [TBL] [Abstract][Full Text] [Related]
20. Treatment strategies in patients with rheumatoid arthritis for whom methotrexate monotherapy has failed: data from the NOR-DMARD register. Lie E; van der Heijde D; Uhlig T; Mikkelsen K; Kalstad S; Kaufmann C; Rødevand E; Kvien TK Ann Rheum Dis; 2011 Dec; 70(12):2103-10. PubMed ID: 21875874 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]